BYETTA (5 µg BID for 4 weeks, followed by 10 µg BID) resulted in statistically significant reductions from baseline HbA1c compared to placebo (-0.8% versus +0.1%) as well as significant reductions in body weight (-1.5 versus -0.2 kg).
BYETTA- raviga (4 nädala jooksul 5 µg 2 korda ööpäevas, seejärel 10 µg 2 korda ööpäevas) kaasnes esialgse HbA1c oluline langus, võrreldes platseeboga (- 0, 8% versus +0, 1%), ja oluline kehakaalu vähenemine (- 1, 5 versus – 0, 2).